Have a personal or library account? Click to login
Distribution of Paraoxonase 1 polymorphisms and activities in obese patients Cover

Distribution of Paraoxonase 1 polymorphisms and activities in obese patients

Revista Romana de Medicina de Laborator
Volume 21 (2013): Issue 4 (December 2013)
By: Lorena Ciumărnean,  Ştefan C. Vesa,  Eleonora Dronca,  Dorel P. Sâmpelean,  Vasile C. Vlad,  Maria S. Moldovan and  Cadariu A. Achimaş  
Open Access
|Dec 2013

References

  1. 1. She Z-G, Chen H-Z, Yan Y, Li H, Liu D-P. The Human Paraoxonase Gene Cluster as a Target in the Treatment of Atherosclerosis. Antioxid Redox Signal. 2012 Mar 15;16(6):597-632.10.1089/ars.2010.3774
    Search in Google Scholar
  2. 2. Kedage V, Muttigi MS, Shetty MS, Suvarna R, Rao SS, Joshi C, et al. Serum Paraoxonase 1 Activity Status in Patients with Liver Disorders. Saudi J Gastroenterol. 2010;16(2):79-83.10.4103/1319-3767.61232
    Search in Google Scholar
  3. 3. Beltowski J, Wójcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis. 2003;170:21-9.10.1016/S0021-9150(03)00236-3
    Search in Google Scholar
  4. 4. Audikovszky M, Pados G, Seres I, Harangi M, Fülöp P, Katona E, et al. Orlistat increases serum paraoxonase activity in obese patients. Nutr Metab Cardiovasc Dis. 2007;17:268-73.10.1016/j.numecd.2006.03.00417134960
    Search in Google Scholar
  5. 5. Veiga L, Silva-Nunes J, Melão A, Oliveira A, Duarte L, Brito M. Q192R polymorphism of the paraoxonase-1 gene as a risk factor for obesity in Portuguese women. Eur J Endocrinol. 2011;164:213-8.10.1530/EJE-10-082521078685
    Search in Google Scholar
  6. 6. Martínez-Salazar MF, Almenares-López D, García- Jiménez S, Sánchez-Alemán MA, Juantorena-Ugás A, Ríos C, et al. Relationship between the paraoxonase (PON1) L55M and Q192R polymorphisms and obesity in a Mexican population: a pilot study. Genes Nutr. 2011;6:361-8.10.1007/s12263-011-0215-0319784721484160
    Search in Google Scholar
  7. 7. Camps J, Marsillach J, Joven J. Measurement of serum paraoxonase-1 activity in the evaluation of liver function. World J Gastroenterol. 2009;15(16):1929-33.10.3748/wjg.15.1929267508119399923
    Search in Google Scholar
  8. 8. Chedid R, Gannagé-Yared MH, Khalifé S, Halaby G, Zoghbi F. Impact of different metabolic syndrome classifications on the metabolic syndrome prevalence in a young Middle Eastern population. Metabolism. 2009;58(6):746-52.10.1016/j.metabol.2008.11.01419446111
    Search in Google Scholar
  9. 9. Paşca SP, Dronca E, Nemeş B, Kaucsár T, Endreffy E, Iftene F, et al. Paraoxonase 1 activities and polymorphisms in autism spectrum disorders. J Cell Mol Med. 2010;14:600-7.
    Search in Google Scholar
  10. 10. Altuner D, Ates I, Suzen SH, Koc GV, Aral Y, Karakaya A. The relationship of PON1 QR 192 and LM polymorphisms with serum paraoxonase activities of Turkish diabetic patients. Toxicol Ind Health. 2011;27(10):873-8.10.1177/074823371139931721505009
    Search in Google Scholar
  11. 11. Grdic Rajkovic M, Rumora L, Barisic K. The paraoxonase 1,2 and 3 in humans. Biochemia Medica. 2011;21(2):122-30.10.11613/BM.2011.020
    Search in Google Scholar
  12. 12. ATP III Final Report PDF: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report Circulation. 2002;106:3143.10.1161/circ.106.25.3143
    Search in Google Scholar
  13. 13. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20;120(16):1640-5.10.1161/CIRCULATIONAHA.109.19264419805654
    Search in Google Scholar
  14. 14. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva: World Health Organization (accessed in February 2013). Available at http://whqlibdoc.who.int/trs/WHO_TRS_894.pdf.
    Search in Google Scholar
  15. 15. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet. 1983;35(2):214-27.
    Search in Google Scholar
  16. 16. Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 2004;44:6371-82.10.1021/bi047440d15835926
    Search in Google Scholar
  17. 17. Gupta N, Singh S, Maturu VN, Sharma YP, Gill KD.Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting CAD risk in North-West Indian Punjabis. PLoS One. 2011;6(5):e17805.10.1371/journal.pone.0017805310120221629682
    Search in Google Scholar
  18. 18. Kotani K, Sakane N, Sano Y, Tsuzaki K, Matsuoka Y, Eqawa K et al. Change on the Physiological Lactonase Activity of Serum Paraoxonase 1 by Diet Intervention for Weight Loss in healthy Overweight and Obese Women. J Clin Biochem Nutr. 2009; 45(3):329-34.10.3164/jcbn.09-26277125519902024
    Search in Google Scholar
  19. 19. Kordi-Tamandani DM, Hashemi M, Sharifi N, Kaykhaei MA, Torkamanzehi A. Association between paraoxonase-1 gene polymorphisms and risk of metabolic syndrome. Mol Biol Rep. 2012;39:937-43.10.1007/s11033-011-0819-x21573798
    Search in Google Scholar
  20. 20. Gorshunskaya MY, Karachentsev YI, Atramentova LA, Tyzhnenko TV, Kravchun NA, Pochernyaev AK, et al. Q192R polymorphism of PON-1 gene in type 2 diabetes patients. Cytol Genet. 2011 Feb 1;45(1):38-40.10.3103/S0095452711010087
    Search in Google Scholar
  21. 21. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochemical Pharmacology; 2005;69:541-50.10.1016/j.bcp.2004.08.02715670573
    Search in Google Scholar
  22. 22. Tabur S, Torun AN, Sabuncu T, Turan MN, Celik H, Ocak AR, et al. Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation.Eur J Endocrinol 2011;162(3):535-41.10.1530/EJE-09-073220022940
    Search in Google Scholar
  23. 23. Rogulj D, Konjevoda P, Milić M, Mladinić M, Domijan AM. Fatty liver index as an indicator of metabolic syndrome. Clin Bioche. 2012;45(1-2):68-71.10.1016/j.clinbiochem.2011.10.01422056738
    Search in Google Scholar
  24. 24. Ferretti G, Bacchetti T, Masciangelo S, Bicchiega V. HDL-paraoxonase and Membrane Lipid Peroxidation: A Comparison Between Healthy and Obese Subjects.Obesity. 2010;18(6):1079-84.10.1038/oby.2009.33819834469
    Search in Google Scholar
  25. 25. Roest M, van Himbergen TM, Barendrecht AB, Peeters PH, van der Schouw YT, Voorbij HA. Genetic and environmental determinants of the PON-1 phenotype. Eur J Clin Invest. 2007;37:187-96.10.1111/j.1365-2362.2007.01769.x17359486
    Search in Google Scholar
DOI: https://doi.org/10.2478/rrlm-2013-0037 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Journal RSS Feed
Language: English
Page range: 381 - 389
Published on: Dec 31, 2013
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
paraoxonase,
arylesterase,
lactonase,
activity,
genotype,
obesity
Related subjects:
Life sciences,
Molecular biology,
Biochemistry,
Human biology,
Microbiology and virology

© 2013 Lorena Ciumărnean, Ştefan C. Vesa, Eleonora Dronca, Dorel P. Sâmpelean, Vasile C. Vlad, Maria S. Moldovan, Cadariu A. Achimaş, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons License.

Volume 21 (2013): Issue 4 (December 2013)